Back to top

Prelude Therapeutics Appoints Paul Scherer as Director

Prelude Therapeutics ( ($PRLD) ) just unveiled an update. On June 11, 2025, Prelude Therapeutics appointed Paul Scherer, M.D., as a Class III direc...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Prelude Therapeutics Incorporated (PRLD)